Veraxa Biotech Holding AG (NASDAQ:VRXA) Short Interest Down 46.3% in August

Veraxa Biotech Holding AG (NASDAQ:VRXA) saw a large drop in short interest in August. As of August 31st, there was short interest totaling 202,960 shares, a drop of 46.3% from the August 15th total of 378,219 shares. Currently, 0.6% of the company’s stock are short sold. Based on an average trading volume of 204,024 shares, the days-to-cover ratio is presently 1.0 days.

Insider Transactions at Veraxa Biotech

In other Veraxa Biotech news, Director Oliver Rolf Baumann purchased 50,000 shares of the stock in a transaction that occurred on Thursday, August 27th. The stock was bought at an average cost of $1.50 per share, with a total value of $75,000.00. Following the transaction, the director directly owned 5,773,618 shares in the company, valued at approximately $8,660,427. The trade was a 0.87% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of Veraxa Biotech from a “sell” rating to a “hold” rating in a report on Monday, August 31st.

Veraxa Biotech Price Performance

Shares of NASDAQ VRXA traded down $0.01 during trading on Wednesday, reaching $1.51. The company had a trading volume of 47,558 shares, compared to its average volume of 405,431. Veraxa Biotech has a 12-month low of $1.27 and a 12-month high of $27.36.

Veraxa Biotech Company Profile

Veraxa Biotech AG is a biotechnology company focused on developing targeted antibody-based medicines, with an emphasis on antibody-drug conjugates (ADCs). These therapies are designed to use antibodies to identify specific cells and deliver therapeutic agents more selectively.

The company’s work includes antibody discovery, therapeutic development and the design of ADC candidates that combine targeting antibodies with drug payloads. Its research is directed primarily toward potential treatments for cancer and other serious diseases, although specific development programs and product approvals may change as its pipeline advances.

Publicly available information about Veraxa Biotech’s corporate history, geographic operations and leadership is limited.